ReviewTranslational lung cancer research2017
Intraoperative adjuncts for malignant pleural mesothelioma.
Review in Translational lung cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- A Clinical Trial of TumorGlow to Identify Residual Disease During Pleurectomy and Decortication.The Annals of thoracic surgery · 2019Trial
- Optimal surgery for resectable malignant pleural mesothelioma in the setting of multimodality treatment.Surgery today · 2024Review
- Feasibility and safety of extended pleurectomy/decortication for malignant pleural mesothelioma. A single group experience.Thoracic cancer · 2022Article
- An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma.Lung Cancer (Auckland, N.Z.) · 2022Review
- Landmark Trials in the Surgical Management of Mesothelioma.Annals of surgical oncology · 2021Review
- Povidone-iodine results in rapid killing of thymic epithelial tumour cells through cellular fixation†.Interactive cardiovascular and thoracic surgery · 2019Article
- Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model.Journal of thoracic disease · 2018Article
- The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.Journal of thoracic disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common. Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic therapy (PDT) target micrometastatic disease and aim to improve local control. This review details the most recent studies and trials of HIOC, heated intraoperative PVP-I, and PDT, this aims to provide an update on some of the most promising intraoperative adjuncts for patients with MPM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.